ASO Author Reflections: Can Perioperative Ghrelin Administration Inhibit Postoperative Muscle Mass Loss in Esophageal Cancer Patients?

Ann Surg Oncol. 2022 Jun;29(6):3613-3614. doi: 10.1245/s10434-022-11437-z. Epub 2022 Feb 15.

Authors

Yohei Nose¹, Kotaro Yamashita², Tomohira Takeoka³, Kota Momose⁴, Takuro Saito¹, Koji Tanaka¹, Kazuyoshi Yamamoto¹, Tomoki Makino¹, Tsuyoshi Takahashi¹, Yukinori Kurokawa¹, Makoto Yamasaki¹, Osamu Shiraishi⁴, Hiroshi Miyata³, Takushi Yasuda⁴, Masahiko Yano³, Hidetoshi Eguchi¹, Yuichiro Doki¹

Affiliations

¹ Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
² Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. kyamashita@gesurg.med.osaka-u.ac.jp.
³ Department of Surgery, Osaka International Cancer Institute, Osaka, Japan.
⁴ Department of Gastroenterological Surgery, Graduate School of Medicine, Kindai University, Osaka, Japan.

PMID: 35166955
DOI: 10.1245/s10434-022-11437-z

No abstract available

Publication types

Comment

MeSH terms

Esophageal Neoplasms* / drug therapy
Esophageal Neoplasms* / surgery
Esophagectomy / adverse effects
Ghrelin
Humans
Muscles
Muscular Diseases*
Rare Diseases

Substances

Ghrelin